Pilates Instructor’s ‘Flu’ Turns Out to Be Aggressive Lymphoma, But Immunotherapy Offers Hope
Debi Weiss, a 72-year-old Pilates instructor, initially dismissed her declining health as the flu. Still, she received a shocking diagnosis of diffuse large B-cell lymphoma (DLBCL), a fast-growing cancer of the lymphatic system.1,2,3 After chemotherapy failed to provide a lasting remission, Weiss underwent CAR-T immunotherapy and is now in complete remission, with a renewed focus on family and prioritizing her well-being.
Initial Symptoms and Diagnosis
In January 2024, Weiss began experiencing weakness and shortness of breath.1 As weeks passed, her symptoms worsened, making it challenging to walk her dog and leaving her constantly exhausted.1 A visit to her primary care provider in March 2024 led to testing that suggested an aggressive form of cancer. Subsequent blood tests and a biopsy confirmed a diagnosis of diffuse large B-cell lymphoma.1
Chemotherapy and Recurrence
Weiss initially responded well to chemotherapy, with fatigue being her only significant side effect.1 However, one month after completing chemotherapy, she began experiencing neurological issues, and imaging revealed the lymphoma had recurred in her brain.1 Dr. Charles Farber, a hematologist-oncologist at Atlantic Health Morristown Medical Center, described her prognosis as “dismal,” but a chance for personalized immunotherapy offered a glimmer of hope.1
CAR-T Immunotherapy: A New Approach
In January 2025, Weiss underwent CAR-T (chimeric antigen receptor T-cell) immunotherapy.2,3 This innovative treatment involves removing a patient’s T-cells, genetically engineering them to recognize and attack cancer cells, and then infusing them back into the body.2,4 Dr. Mohamad Cherry, the medical director of hematology at Atlantic Health, explained the process as a “blood transfusion.”2 Weiss described the experience, visualizing her modified cells as “Pac-Man” attacking her cancer cells.2
Remarkable Remission and Shift in Priorities
Weiss experienced no side effects from the CAR-T therapy and was able to return to her daily life, including walking her dog again.2 She is now in “complete remission,” although she will continue to undergo scans every four to six months to monitor for any recurrence.1
The cancer journey prompted a significant shift in Weiss’s priorities. She now prioritizes spending time with her family and focusing on activities she genuinely enjoys.1 “Life is better than it was before in a lot of ways,” Weiss said. “Your priorities change…Now, if my family needs me, I don’t work.”1
Understanding Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma is the most common type of lymphoma, accounting for approximately 25,000 cases each year in the United States.1 It is characterized by rapid growth and can be challenging to diagnose.1
Disclaimer: I am an AI chatbot and cannot provide medical advice. This information is for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Worth a look
- Sacheon Inspects 208 Convenience and Unmanned Food Stores for Food Safety
- WakeMed CEO Addresses Possible Atrium Merger and Patient Costs
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)
- Trump resists AI slowdown as the political tide turns (newsylist.com)